Stay updated with breaking news from Real World Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.
The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.
Experts on mantle cell lymphoma discuss second-line treatment options available for patients.
Richard Furman, MD, outlines his strategy for addressing BTK inhibitor intolerance in CLL patients, underscoring the significance of BTK inhibitors in CLL treatment and advocating for transitioning to an alternative BTK inhibitor rather than completely discontinuing the class in cases of drug intolerance.
/PRNewswire/ -- ConcertAI, the leader in oncology Real-World Data (RWD) and AI SaaS Solutions and for healthcare and life sciences, today announced Jennifer...